NCT05644093View on ClinicalTrials.gov

IM and IV SPL026 Drug Product in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

April 5, 2023

Study Completion Date

April 5, 2023

Conditions

Major Depressive Disorder

Interventions

DRUG

SPL026 IV

IV dosing

DRUG

SPL026 IM

IM dosing

Trial Locations (1)

Unknown

Hammersmith Medicines Research, London

All Listed Sponsors

lead

Small Pharma Ltd

INDUSTRY